Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2025-09-24 Capital/Financing Update
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a media release announcing a new exclusive license and collaboration agreement between Glenmark Pharmaceuticals and Hengrui Pharma regarding a HER2-targeting ADC drug. It contains no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. It is a corporate announcement about a strategic partnership and product development, not a financial report or regulatory filing. The document is about a capital or strategic collaboration update, which fits best under Capital/Financing Update (CAP) as it relates to a significant licensing and collaboration agreement involving upfront payments and milestone payments. The document length is 7591 characters, which is sufficient for a detailed announcement but does not contain financial statements or earnings data. Therefore, the most appropriate classification is CAP with high confidence.
2025-09-24 English
Record Date
Notice of Dividend Amount Classification · 90% confidence The document is a letter dated September 22, 2025, addressed to the stock exchanges regarding a Board Meeting scheduled for September 26, 2025. The purpose of the meeting is to consider and approve payment of an interim dividend for the financial year 2025-26. The letter also informs about a revised record date for payment of the interim dividend. The document is short (1895 characters) and serves as an announcement or notification about the dividend payment and related dates. It does not contain actual financial statements or detailed financial data, nor is it a full report. It is not a dividend amount notice per se, as it does not specify the dividend amount, only the record date and meeting information. However, the closest fitting category is Notice of Dividend Amount (DIV), since it relates to dividend payment scheduling and record date, which is typically part of dividend announcements. Given the content, the best classification is DIV with high confidence.
2025-09-22 English
Trading Window
Board/Management Information Classification · 95% confidence The document is a letter from Glenmark Pharmaceuticals Limited addressed to stock exchanges and regulatory bodies. It announces a forthcoming Board Meeting scheduled for September 26, 2025, to consider and approve the payment of an interim dividend for the financial year 2025-26. It also mentions the record date for the dividend payment and the closure of the trading window as per insider trading regulations. The document does not contain any financial statements, detailed financial data, or comprehensive report content. Instead, it is an announcement about a Board Meeting and related corporate actions. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or meetings involving the company's board of directors or senior management.
2025-09-22 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-09-22 English
Record Date
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges and regulatory bodies, informing about an upcoming Board Meeting scheduled for September 26, 2025. The purpose of the meeting includes consideration and approval of an interim dividend for the financial year 2025-26. It also mentions the record date for the dividend payment and the closure of the trading window as per insider trading regulations. The document does not contain any financial statements, detailed financial data, or comprehensive report content. Instead, it is an announcement about a board meeting and related corporate actions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or meetings involving the company's board of directors or senior management. The document length is short (2351 characters), and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is MANG with high confidence.
2025-09-22 English
Board Meeting — Dividend
Board/Management Information Classification · 95% confidence The document is a letter from Glenmark Pharmaceuticals Limited addressed to stock exchanges and regulatory bodies. It announces a forthcoming Board Meeting scheduled for September 26, 2025, to consider and approve the payment of an interim dividend for the financial year 2025-26. It also mentions the record date for the dividend payment and the closure of the trading window for insiders. The document is short (2351 characters) and serves as an announcement of a board meeting and related corporate actions, not a full report or financial statement. It does not contain financial data or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or meetings of the board of directors or senior management.
2025-09-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.